Press release
Rising Incidence Of Neurodegenerative Disorders Fueling The Growth Of The Market Due To Aging Population And Increasing Demand For Effective Therapies: Strengthening the Growth Trajectory of the Cathepsin Inhibitor Market
Cathepsin Inhibitor Market
What Is the Expected CAGR for the Cathepsin Inhibitor Market Through 2025?
In previous years, the market size for the cathepsin inhibitor has seen significant growth. It's projected that it'll expand from $0.76 billion in 2024 to $0.83 billion by 2025, with a compound annual growth rate (CAGR) of 10.0%. The growth observed in the historical period can be linked to factors like the escalating cancer rates, increased occurrence of inflammatory conditions, growth of investment in drug analysis, progress in protease investigation, and its broadening application in treating bone disorders.
What's the Projected Size of the Global Cathepsin Inhibitor Market by 2029?
In the forthcoming years, the cathepsin inhibitor market size is projected to experience swift expansion, reaching "$1.24 billion in 2029" with a 10.4% compound annual growth rate (CAGR). The growth during the forecasted period can be credited to a surge in targeted therapies, a heightened focus on neurodegenerative disease treatments, increased funding in R&D, a rising demand for precision medicine, and a surge in applications for infectious disease treatment. Key trends for the forecast period encompass the introduction of selective cathepsin inhibitors, partnerships among biotech companies, emphasis on oral drug formulations, the application of artificial intelligence in drug discovery, and a widening scope into rare disease therapeutics.
View the full report here:
https://www.thebusinessresearchcompany.com/report/cathepsin-inhibitor-global-market-report
Top Growth Drivers in the Cathepsin Inhibitor Industry: What's Accelerating the Market?
The escalating prevalence of neurodegenerative disorders is anticipated to drive the expansion of the cathepsin inhibitor market. Neurodegenerative disorders are typically advancing and often incurable conditions marked by the steady degeneration or loss of neurons in the central nervous system, mostly affecting the brain. The escalation in neurodegenerative disorders is firmly connected to the aging populace. With the increase in life expectancy, age-related diseases such as Alzheimer's and Parkinson's become more widespread, exerting additional strain on healthcare infrastructures. Cathepsin inhibitors are being examined as prospective therapeutic agents in neurodegenerative disorders due to their contribution in adjusting amyloid-beta (Aß) production and neuroinflammation. For instance, data from the Alzheimer's Association, a US-based nonprofit health organization, predict that, in 2024, around 6.9 million Americans aged 65 and above will be living with Alzheimer's dementia. This figure is projected to nearly double to 13.8 million by 2060. Consequently, the escalating prevalence of neurodegenerative disorders is fueling the expansion of the cathepsin inhibitor market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24185&type=smp
What Long-Term Trends Will Define the Future of the Cathepsin Inhibitor Market?
The key corporations in the cathepsin inhibitor market are prioritizing strategic alliances to inspire drug discovery innovation, broaden their product range, and facilitate rapid market penetration. These strategic partnerships aim to exploit mutual expertise and resources to boost the success rates of clinical trials and increase the chances of regulatory approvals. For example, in June 2024, the Japanese drug discovery company Alivexis sealed an exclusive licensing contract with Melodia Therapeutics, a Swiss-based biotech firm. This agreement granted Melodia global rights for the development, manufacture and marketing of MDI-0151, an innovative cathepsin C inhibitor. Discovered in Alivexis' MOD-A discovery program, MDI-0151 targets inflammatory conditions driven by neutrophils, such as ANCA-associated vasculitis. Melodia is planning to set off IND-enabling activities to get ready for Phase 1/2a studies in these indications, with the goal to procure clinical proof of concept.
What Are the Main Segments in the Cathepsin Inhibitor Market?
The cathepsin inhibitor market covered in this report is segmented -
1) By Type: Small Molecule Inhibitors, Peptide Inhibitors, Monoclonal Antibodies
2) By Application: Cancer Treatment, Autoimmune Diseases, Inflammatory Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospitals And Clinics
4) By End User: Pharmaceutical Companies, Academic And Research Institutes, Contract Research Organizations (CROs)
Subsegments:
1) Small Molecule Inhibitors: Reversible Inhibitors, Irreversible Inhibitors, Synthetic Compounds, Natural Product-Derived Inhibitors
2) Peptide Inhibitors: Linear Peptides, Cyclic Peptides, Modified Peptides, Peptidomimetics
3) Monoclonal Antibodies: Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Antibodies
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24185&type=smp
Which Top Companies are Driving Growth in the Cathepsin Inhibitor Market?
Major companies operating in the cathepsin inhibitor market are Merck KGaA, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bio-Techne Corporation, AddLife AB, BioVision, R&D Systems Inc., Cayman Chemical, Selleck Chemicals, Santa Cruz Animal Health, Tocris Bioscience, Virobay Inc., MedChemExpress, BOC Sciences, Biorbyt Ltd, GlpBio Technology, Echelon Biosciences, AG Scientific, ApexBio Technology, OXiGENE Inc.
Which Regions Will Dominate the Cathepsin Inhibitor Market Through 2029?
North America was the largest region in the cathepsin Inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cathepsin inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24185
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Incidence Of Neurodegenerative Disorders Fueling The Growth Of The Market Due To Aging Population And Increasing Demand For Effective Therapies: Strengthening the Growth Trajectory of the Cathepsin Inhibitor Market here
News-ID: 4183965 • Views: …
More Releases from The Business Research Company
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the M …
The meal replacement market is gaining significant momentum as consumer preferences shift toward convenient and health-focused nutrition solutions. With rising awareness about preventive healthcare and personalized diets, this sector is set for considerable expansion. Let's explore how the market size is expected to evolve, who the key players are, emerging trends, and the main segments driving this growth.
Projected Growth Trajectory of the Meal Replacement Market Size
The meal replacement…
Leading Companies Reinforcing Their Presence in the Malted Barley Market
The malted barley industry is positioned for steady expansion as demand grows across various sectors. With increasing interest from craft brewers and functional food producers, this market is set to experience meaningful growth driven by innovation and sustainability efforts. Let's dive into the current market size, key players shaping the industry, trends influencing its trajectory, and detailed segment insights.
Projected Market Size and Growth Outlook of the Malted Barley Market …
Future Perspective: Key Trends Shaping the Low-calorie Food Market up to 2030
The low-calorie food market is poised for significant expansion as consumer preferences shift toward healthier eating habits and more personalized nutrition options. Advances in product innovation and supportive regulatory frameworks are expected to drive rapid growth over the coming years. Here's an overview of the market size, key players, emerging trends, and segmentation shaping this evolving industry.
Projected Expansion of the Low-calorie Food Market Size Through 2030
The low-calorie food…
Competitive Landscape: Leading Companies and New Entrants in the Liquid Nutritio …
The liquid nutritional supplement sector is on the rise, driven by evolving consumer preferences and innovations in health and wellness. With growing awareness about personalized nutrition and preventive healthcare, this market is set to witness substantial growth over the coming years. Let's explore the market's projected size, major players, emerging trends, and key segments shaping this dynamic industry.
Projected Market Value and Growth Trajectory of the Liquid Nutritional Supplement Market …
More Releases for Inhibitor
Advances in KRAS Inhibitor Development
The development of KRAS inhibitors has been a significant advancement in the field of oncology, offering new hope for patients with cancers driven by KRAS mutations. KRAS, a key gene involved in cell signaling, is frequently mutated in various cancers, including lung, colorectal, and pancreatic cancers. These mutations lead to uncontrolled cell growth and division, making KRAS a critical target for cancer therapy.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
Historically, KRAS was considered an undruggable target…
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable."
Download…
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview
The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030.
Understanding Checkpoint Inhibitor Refractory Cancer
Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of…
Fibroblast Growth Factor Receptor Inhibitor Market - Maximizing Therapeutic Pote …
Newark, New Castle, USA: The "Fibroblast Growth Factor Receptor Inhibitor Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Fibroblast Growth Factor Receptor Inhibitor Market: https://www.growthplusreports.com/report/fibroblast-growth-factor-receptor-inhibitor-market/8933
This latest report…
Global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) Market Forecast 2023- …
The global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) market research report helps target customers understand the important driving factors and future opportunities of the industry. The report includes the dynamics of the macro environment such as the latest situation of the war between Russia and Ukraine, the update of monetary policy, and the impact of inflation on the market. Apart from this, the report studies key market developments such as…
Avionic and electronic component corrosion inhibitor
Super CORR A was originally developed for the U.S. Air Force to comply with Mil-DTL-87177B (formerly Mil-L-87177A) specifications. A water displacing lubricant and corrosion protection compound that prevents avionic as well as electrical and electronic components from systems failures caused by corrosion. It is now the industry standard for electrical corrosion protection, for in service maintenance by both military and commercial aircraft major repair and overhaul (MRO) facilities worldwide.
Super CORR…
